Chong Kun Dang Pharmaceutical (XKRX:185750) LT-Debt-to-Total-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Chong Kun Dang Pharmaceutical's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.03.

Chong Kun Dang Pharmaceutical's long-term debt to total assets ratio declined from Mar. 2023 (0.09) to Mar. 2024 (0.03). It may suggest that Chong Kun Dang Pharmaceutical is progressively becoming less dependent on debt to grow their business.

Chong Kun Dang Pharmaceutical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical LT-Debt-to-Total-Asset Chart

Chong Kun Dang Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.06

0.13

0.10

0.03

Chong Kun Dang Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.11	0.03	0.03	0.03

Chong Kun Dang Pharmaceutical LT-Debt-to-Total-Asset Calculation

Chong Kun Dang Pharmaceutical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	34996.514	/	1402428.436
	=	0.02

Chong Kun Dang Pharmaceutical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	41212.786	/	1414821.246
	=	0.03

Chong Kun Dang Pharmaceutical (XKRX:185750) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Chong Kun Dang Pharmaceutical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756

Website

http://chongkundang.en.ec21.com

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines